Investigation Of The C-Met Signaling Pathway In A Renal Carcinoma Cancer Cell Line

Project no. 32855 · Status: Kapanmış (Yayın bekleniyor) · 2025

Summary

<p class="ql-align-justify">Cancer&nbsp;is&nbsp;rapidly&nbsp;increasing&nbsp;today.&nbsp;Renal&nbsp;cell&nbsp;carcinoma&nbsp;(RCC)&nbsp;is&nbsp;one&nbsp;of&nbsp;the&nbsp;10&nbsp;most&nbsp;common&nbsp;and&nbsp;widespread&nbsp;cancers&nbsp;worldwide.&nbsp;It&nbsp;is&nbsp;the&nbsp;most&nbsp;common&nbsp;type&nbsp;of&nbsp;kidney&nbsp;cancer&nbsp;in&nbsp;adults,&nbsp;accounting&nbsp;for&nbsp;approximately&nbsp;90–95%&nbsp;of&nbsp;cases.&nbsp;Although&nbsp;surgical&nbsp;resection&nbsp;is&nbsp;the&nbsp;primary&nbsp;curative&nbsp;approach&nbsp;for&nbsp;RCC,&nbsp;a&nbsp;significant&nbsp;number&nbsp;of&nbsp;patients&nbsp;experience&nbsp;disease&nbsp;recurrence.&nbsp;In&nbsp;this&nbsp;context,&nbsp;the&nbsp;development&nbsp;of&nbsp;targeted&nbsp;therapies—such&nbsp;as&nbsp;tyrosine&nbsp;kinase&nbsp;inhibitors&nbsp;(TKIs),&nbsp;mammalian&nbsp;target&nbsp;of&nbsp;rapamycin&nbsp;(mTOR)&nbsp;inhibitors,&nbsp;and&nbsp;immune&nbsp;checkpoint&nbsp;inhibitors—has&nbsp;marked&nbsp;a&nbsp;significant&nbsp;turning&nbsp;point&nbsp;in&nbsp;the&nbsp;treatment&nbsp;of&nbsp;metastatic&nbsp;renal&nbsp;cell&nbsp;carcinoma.&nbsp;As&nbsp;research&nbsp;into&nbsp;the&nbsp;biology&nbsp;of&nbsp;human&nbsp;neoplasms&nbsp;has&nbsp;increased,&nbsp;molecularly&nbsp;targeted&nbsp;agents—which&nbsp;generally&nbsp;demonstrate&nbsp;higher&nbsp;efficacy&nbsp;and&nbsp;lower&nbsp;toxicity—have&nbsp;been&nbsp;replacing&nbsp;traditional&nbsp;cytotoxic&nbsp;and&nbsp;cytostatic&nbsp;regimens&nbsp;in&nbsp;cancer&nbsp;treatment&nbsp;over&nbsp;the&nbsp;past&nbsp;decade.&nbsp;This&nbsp;trend&nbsp;is&nbsp;significantly&nbsp;impacting&nbsp;treatment&nbsp;options.&nbsp;In&nbsp;this&nbsp;context,&nbsp;our&nbsp;study&nbsp;investigating&nbsp;the&nbsp;c-Met&nbsp;pathway&nbsp;in&nbsp;a&nbsp;renal&nbsp;carcinoma&nbsp;cell&nbsp;line&nbsp;will&nbsp;identify&nbsp;potential&nbsp;implications&nbsp;for&nbsp;cancer&nbsp;biology&nbsp;and&nbsp;treatment&nbsp;strategies.&nbsp;The&nbsp;c-Met&nbsp;pathway&nbsp;is&nbsp;responsible&nbsp;for&nbsp;cell&nbsp;proliferation,&nbsp;growth,&nbsp;invasion,&nbsp;cell&nbsp;migration,&nbsp;proliferation,&nbsp;and&nbsp;the&nbsp;cell&nbsp;cycle.&nbsp;Its&nbsp;irregular&nbsp;activation&nbsp;leads&nbsp;to&nbsp;the&nbsp;formation&nbsp;of&nbsp;cancer&nbsp;cells&nbsp;and&nbsp;promotes&nbsp;their&nbsp;proliferation&nbsp;and&nbsp;growth.&nbsp;The&nbsp;c-Met&nbsp;protein&nbsp;is&nbsp;a&nbsp;transmembrane&nbsp;receptor&nbsp;tyrosine&nbsp;kinase.&nbsp;Its&nbsp;only&nbsp;known&nbsp;ligand,&nbsp;hepatocyte&nbsp;growth&nbsp;factor&nbsp;(HGF)/spread&nbsp;factor&nbsp;(SF),&nbsp;regulates&nbsp;cell&nbsp;growth,&nbsp;migration,&nbsp;invasion,&nbsp;proliferation,&nbsp;and&nbsp;angiogenesis.&nbsp;This&nbsp;project&nbsp;focuses&nbsp;on&nbsp;understanding&nbsp;the&nbsp;molecular&nbsp;mechanisms&nbsp;of&nbsp;the&nbsp;c-Met&nbsp;signaling&nbsp;pathway&nbsp;in&nbsp;a&nbsp;renal&nbsp;carcinoma&nbsp;cell&nbsp;line.&nbsp;The&nbsp;study&nbsp;will&nbsp;analyze&nbsp;the&nbsp;effects&nbsp;of&nbsp;c-Met&nbsp;inhibition&nbsp;on&nbsp;cell&nbsp;proliferation,&nbsp;gene&nbsp;expression&nbsp;profiles,&nbsp;and&nbsp;apoptosis.&nbsp;To&nbsp;this&nbsp;end,&nbsp;c-Met&nbsp;inhibitors&nbsp;such&nbsp;as&nbsp;foretinib&nbsp;will&nbsp;be&nbsp;used.&nbsp;Cell&nbsp;culture&nbsp;experiments&nbsp;will&nbsp;be&nbsp;conducted&nbsp;to&nbsp;assess&nbsp;cell&nbsp;viability,&nbsp;cell&nbsp;proliferation,&nbsp;and&nbsp;real-time&nbsp;quantitative&nbsp;polymerase&nbsp;chain&nbsp;reaction.&nbsp;In&nbsp;addition,&nbsp;cell&nbsp;viability&nbsp;and&nbsp;proliferation&nbsp;will&nbsp;be&nbsp;measured&nbsp;using&nbsp;appropriate&nbsp;kits,&nbsp;and&nbsp;cellular&nbsp;changes&nbsp;will&nbsp;be&nbsp;evaluated&nbsp;through&nbsp;apoptosis&nbsp;analysis.&nbsp;Gene&nbsp;expression&nbsp;will&nbsp;be&nbsp;assessed&nbsp;via&nbsp;qPCR.&nbsp;The&nbsp;expected&nbsp;results&nbsp;indicate&nbsp;that&nbsp;c-Met&nbsp;may&nbsp;be&nbsp;an&nbsp;effective&nbsp;target&nbsp;in&nbsp;the&nbsp;treatment&nbsp;of&nbsp;renal&nbsp;carcinoma.</p><p></p><p></p><p></p><p></p><p></p><p></p>

View details